About Denali Therapeutics
Denali Therapeutics is a company based in San Francisco (United States) founded in 2015 by Marc Tessier Lavigne and Alexander Schuth.. Denali Therapeutics has raised $347 million across 3 funding rounds from investors including Flagship Pioneering, Baillie Gifford and Arch Venture Partners. The company has 422 employees as of December 31, 2024. Denali Therapeutics has completed 1 acquisition, including Triller. Denali Therapeutics offers products and services including Transport Vehicle Technology. Denali Therapeutics operates in a competitive market with competitors including Biogen, Intra-Cellular Therapies, Amylyx Pharmaceuticals, Poseida Therapeutics and Annexon, among others.
- Headquarter San Francisco, United States
- Employees 422 as on 31 Dec, 2024
- Founders Marc Tessier Lavigne, Alexander Schuth
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Denali Therapeutics Inc.
-
Annual Revenue
$0-100as on Dec 31, 2024
-
Net Profit
$-422.77 M-191.12as on Dec 31, 2024
-
EBITDA
$-494.08 M-174.53as on Dec 31, 2024
-
Total Equity Funding
$347 M (USD)
in 3 rounds
-
Latest Funding Round
$499.73 M (USD), Post-IPO
Feb 27, 2024
-
Investors
Flagship Pioneering
& 4 more
-
Employee Count
422
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Denali Therapeutics
Denali Therapeutics is a publicly listed company on the NASDAQ with ticker symbol DNLI in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Denali Therapeutics
Denali Therapeutics offers a comprehensive portfolio of products and services, including Transport Vehicle Technology. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Enables brain delivery for neurodegenerative disease treatments.
Unlock access to complete
Unlock access to complete
Leadership Team
50 people
Senior Team
34 people
Principal Team
21 people
Product Management Team
15 people
Operations Team
15 people
Software Development Team
13 people
Finance and Accounting
10 people
Scientist Team
9 people
Unlock access to complete
Funding Insights of Denali Therapeutics
Denali Therapeutics has successfully raised a total of $347M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $499.73 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Post-IPO — $499.7M
-
First Round
First Round
(14 May 2015)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2024 | Amount | Post-IPO - Denali Therapeutics | Valuation |
investors |
|
| Aug, 2016 | Amount | Series B - Denali Therapeutics | Valuation |
investors |
|
| May, 2015 | Amount | Series A - Denali Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Denali Therapeutics
Denali Therapeutics has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Flagship Pioneering, Baillie Gifford and Arch Venture Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on life science companies
|
Founded Year | Domain | Location | |
|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
|
Founded Year | Domain | Location | |
|
Life sciences-focused venture capital firm
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Denali Therapeutics
Denali Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Triller. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Music videos are created and shared through a mobile platform.
|
2015 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Denali Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Denali Therapeutics Comparisons
Competitors of Denali Therapeutics
Denali Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Intra-Cellular Therapies, Amylyx Pharmaceuticals, Poseida Therapeutics and Annexon, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for psychiatric and neurologic diseases
|
|
| domain | founded_year | HQ Location |
Small-molecule therapeutics for neurodegenerative diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Denali Therapeutics
Frequently Asked Questions about Denali Therapeutics
When was Denali Therapeutics founded?
Denali Therapeutics was founded in 2015.
Where is Denali Therapeutics located?
Denali Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is Denali Therapeutics a funded company?
Denali Therapeutics is a funded company, having raised a total of $347M across 3 funding rounds to date. The company's 1st funding round was a Series A of $217M, raised on May 14, 2015.
How many employees does Denali Therapeutics have?
As of Dec 31, 2024, the latest employee count at Denali Therapeutics is 422.
What does Denali Therapeutics do?
Denali Therapeutics was founded in 2015 and is headquartered in San Francisco, United States. Operations focus on the biotechnology sector, where therapies for neurodegenerative diseases are developed. The pipeline includes a small molecule RIP1 kinase inhibitor designed to address Alzheimers disease and ALS by modulating inflammatory signaling and glial dysfunction in the brain. An LRRK2 inhibitor is also advanced for Parkinsons disease treatment.
Who are the top competitors of Denali Therapeutics?
Denali Therapeutics's top competitors include Intra-Cellular Therapies, Juno Therapeutics and Entrada Therapeutics.
What products or services does Denali Therapeutics offer?
Denali Therapeutics offers Transport Vehicle Technology.
Is Denali Therapeutics publicly traded?
Yes, Denali Therapeutics is publicly traded on NASDAQ under the ticker symbol DNLI.
How many acquisitions has Denali Therapeutics made?
Denali Therapeutics has made 1 acquisition, including Triller.
Who are Denali Therapeutics's investors?
Denali Therapeutics has 5 investors. Key investors include Flagship Pioneering, Baillie Gifford, Arch Venture Partners, F-Prime Capital, and Alaska Permanent Fund.
What is Denali Therapeutics's ticker symbol?
The ticker symbol of Denali Therapeutics is DNLI on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.